MoCA vs. MMS: Which Tool to Detect Cognitive Disorders in Oncogeriatric?
Overview
This study concerns elderly patients with cancer with onco-geriatric assessment. This study propose to associate the collection of the results with the Mini-Cog and the CODEX with the passing of the MoCA and the MMS tests, as well as a neuropsychological assessment, in order to determine if the patients have cognitive impairments, to evaluate the sensitivity of these 4 screening tests in elderly patients seeking treatment for their cancer. The results of this study will make it possible, where appropriate, to adapt the practice in the context of oncogeriatric assessment.
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Other
- Masking: Single (Participant)
- Study Primary Completion Date: October 13, 2023
Interventions
- Other: Passation of neuropsychological test
- Passation of MoCA and MMS tests associated with neuropsychological test
Clinical Trial Outcome Measures
Primary Measures
- Evaluate the sensitivity of MoCA test
- Time Frame: Up 2 months after inclusion, before initiation of treatment
- MoCA is considered clinically relevant if its sensitivity to identify patients with cognitive impairment is at least 75%
Participating in This Clinical Trial
Inclusion Criteria
- Patient aged over 70 years – Patient with cancer (solid tumor or haemopathy) for whom a first line treatment is envisaged (whatever it is). Surgery and radiotherapy are allowed before entry into the study. – Patient candidate for oncogeriatric assessment – Patient agree to participate in the study – Using the French language Exclusion Criteria:
- Primary central nervous system or cerebral metastasis – Evolutionary psychiatric pathology known (e.g. schizophrenia) – Severe Visual and / or Auditory Impairment – Patients unable to respond to cognitive tests – Patient (s) deprived of liberty, under guardianship or curatorship – Refusal of participation
Gender Eligibility: All
Minimum Age: 70 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Centre Francois Baclesse
- Collaborator
- UCOG (Unite de coordination en Onco-Gériatrie)
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- florence JOLY, prof, Principal Investigator, Centre François Baclesse
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.